Influenza Vaccine Given to Pregnant Women Reduces Hospitalization Due to Influenza in Their Infants
Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged !6 months. Effective approaches are needed to protect this vulnerable population. Vacc...
Saved in:
| Published in | Clinical infectious diseases Vol. 51; no. 12; pp. 1355 - 1361 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
The University of Chicago Press
15.12.2010
University of Chicago Press Oxford University Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged !6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results. Methods. In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding. Results. The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ⩾6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%–98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%–97.8%; P = .001). Conclusions. Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. |
|---|---|
| AbstractList | Background.
Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged !6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results.
Methods.
In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding.
Results.
The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ⩾6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%–98.1%;
P
= .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%–97.8%;
P
= .001).
Conclusions.
Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged <6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results.BACKGROUNDInfants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged <6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results.In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding.METHODSIn a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding.The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ≥6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%-98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%-97.8%; P = .001).RESULTSThe mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ≥6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%-98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%-97.8%; P = .001).Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life.CONCLUSIONSInfluenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged <6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results. In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding. The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ≥6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%-98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%-97.8%; P = .001). Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged <6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results. Methods. In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding. Results. The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ≥6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%-98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%-97.8%; P = .001). Conclusions. Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged !6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results. Methods. In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding. Results. The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ⩾6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%–98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%–97.8%; P = .001). Conclusions. Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged !6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results. Methods. In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding. Results. The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ⩾6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%-98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%-97.8%; P = .001). Conclusions. Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however, no vaccine is approved for infants aged <6 months. Effective approaches are needed to protect this vulnerable population. Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results. In a matched case-control study, case patients were infants aged <12 months admitted to a large urban hospital in the northeastern United States because of laboratory-confirmed influenza from 2000 to 2009. For each case, we enrolled 1 or 2 control subjects who were infants who tested negative for influenza and matched cases by date of birth and date of hospitalization (within 4 weeks). Vaccine effectiveness was calculated on the basis of matched odds ratios and was adjusted for confounding. The mothers of 2 (2.2%) of 91 case subjects and 31 (19.9%) of 156 control subjects aged <6 months, and 1 (4.6%) of 22 case subjects and 2 (5.6%) of 36 control subjects aged ≥6 months, had received influenza vaccine during pregnancy. The effectiveness of influenza vaccine given to mothers during pregnancy in preventing hospitalization among their infants, adjusted for potential confounders, was 91.5% (95% confidence interval [CI], 61.7%-98.1%; P = .001) for infants aged <6 months. The unadjusted effectiveness was 90.7% (95% CI, 59.9%-97.8%; P = .001). Influenza vaccine given to pregnant women is 91.5% effective in preventing hospitalization of their infants for influenza in the first 6 months of life. |
| Author | Gracey, Kristina D. Esposito, Daina B. Benowitz, Isaac Shapiro, Eugene D. Vázquez, Marietta |
| Author_xml | – sequence: 1 givenname: Isaac surname: Benowitz fullname: Benowitz, Isaac organization: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut – sequence: 2 givenname: Daina B. surname: Esposito fullname: Esposito, Daina B. organization: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut – sequence: 3 givenname: Kristina D. surname: Gracey fullname: Gracey, Kristina D. organization: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut – sequence: 4 givenname: Eugene D. surname: Shapiro fullname: Shapiro, Eugene D. organization: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut – sequence: 5 givenname: Marietta surname: Vázquez fullname: Vázquez, Marietta email: marietta.vazquez@yale.edu organization: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23508293$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21058908$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kV1vFCEYhYlpYz_Uf6AZTdQbR2FgGLgxMVW7TbZqmtoabwjLR8t2FlaYaWx_vUxm3dUaryCch5PzvmcPbPngDQCPEHyNIKNvaN1gyO-BXVTjpqQ1R1v5DmtWEobZDthLaQ4hQgzW98FONSgcsl2gjrxte-NvZXEmlXLeFIfu2viiC8WXaC689F1xHhb55cToXplUTEJauk627lZ2LvjifW8GemPkfHF6aVwcnvL39ABsW9km83B17oOvHz-cHkzK6efDo4N301LVkHUl0pawKmfkjbUzhiWzteIzTTikTBNEiEZSUlZZojUnStkGaaJ5zQiuKLZ4H7wdfZf9bGG0Mr6LshXL6BYy3oggnfhb8e5SXIRrgRGkFamywcuVQQw_epM6sXBJmbaV3oQ-CQYZoYRSlMlnd8h56KPP0wmGKEM502D35M886yC_t5-B5ytAJiVbG6VXLm04nPdScZy5FyOnYkgpGrtGEBRD_WKsP4Ov7oAqNzW0lOd17b_40xEP_fL_lo9HZp66EDfZeENJgwe9HHWXOvNzrct4JWiDm1pMvn0XJ2fn9TE5nopP-Bd5ZNJZ |
| CODEN | CIDIEL |
| CitedBy_id | crossref_primary_10_1080_21645515_2018_1483810 crossref_primary_10_1016_j_vaccine_2019_02_019 crossref_primary_10_1093_cid_cix497 crossref_primary_10_1111_aogs_12680 crossref_primary_10_1016_j_vaccine_2020_09_024 crossref_primary_10_3390_jpm11111196 crossref_primary_10_12968_bjom_2017_25_10_624 crossref_primary_10_3389_fimmu_2021_744774 crossref_primary_10_1097_JPN_0000000000000068 crossref_primary_10_1093_infdis_jir513 crossref_primary_10_1093_infdis_jir510 crossref_primary_10_1371_journal_pone_0171499 crossref_primary_10_1080_21645515_2016_1210730 crossref_primary_10_1016_j_vaccine_2017_09_016 crossref_primary_10_1016_j_vaccine_2022_10_023 crossref_primary_10_1016_S1473_3099_17_30190_1 crossref_primary_10_1111_joim_12947 crossref_primary_10_1016_j_vaccine_2024_02_046 crossref_primary_10_4161_21645515_2014_972145 crossref_primary_10_1016_j_celrep_2019_07_047 crossref_primary_10_2807_1560_7917_ES2014_19_45_20959 crossref_primary_10_1007_s10995_012_0957_3 crossref_primary_10_1111_j_1469_0691_2012_03936_x crossref_primary_10_1136_bmjopen_2020_043093 crossref_primary_10_1186_s12889_017_4700_2 crossref_primary_10_2105_AJPH_2012_300676 crossref_primary_10_1002_ijgo_14798 crossref_primary_10_1093_infdis_jix629 crossref_primary_10_1080_21645515_2023_2258627 crossref_primary_10_1097_01_AOG_0000453599_11566_11 crossref_primary_10_1097_INF_0b013e318247f094 crossref_primary_10_1016_j_jvacx_2023_100351 crossref_primary_10_1016_j_vaccine_2020_06_061 crossref_primary_10_1016_j_vaccine_2019_02_001 crossref_primary_10_1007_s40475_019_00188_9 crossref_primary_10_1089_jwh_2024_0893 crossref_primary_10_1136_bmjpo_2022_001545 crossref_primary_10_1371_journal_pone_0160342 crossref_primary_10_3390_vaccines11091402 crossref_primary_10_1016_j_jiph_2017_03_011 crossref_primary_10_1136_bmjopen_2022_066182 crossref_primary_10_1016_j_ajog_2012_06_071 crossref_primary_10_1128_IAI_01120_15 crossref_primary_10_1016_j_ajog_2012_06_072 crossref_primary_10_3389_fimmu_2015_00289 crossref_primary_10_1007_s10995_013_1399_2 crossref_primary_10_3389_fviro_2022_831754 crossref_primary_10_1093_cid_cit599 crossref_primary_10_1371_journal_pone_0122431 crossref_primary_10_1080_21645515_2015_1055428 crossref_primary_10_1016_S0001_4079_19_31686_3 crossref_primary_10_1016_j_jeurea_2015_10_004 crossref_primary_10_1371_journal_pone_0033048 crossref_primary_10_1097_GRF_0b013e31825cfd17 crossref_primary_10_1111_irv_12013 crossref_primary_10_1111_ajo_12034 crossref_primary_10_1186_s13643_016_0347_9 crossref_primary_10_1016_j_vaccine_2020_02_020 crossref_primary_10_1056_NEJMc1412050 crossref_primary_10_1016_j_amepre_2017_10_016 crossref_primary_10_1016_j_vaccine_2016_01_045 crossref_primary_10_1097_OGX_0000000000000283 crossref_primary_10_1093_ofid_ofac552 crossref_primary_10_1517_14740338_2014_977252 crossref_primary_10_1542_pir_35_6_217 crossref_primary_10_1097_01_AOG_0000429661_39212_81 crossref_primary_10_1155_2012_985646 crossref_primary_10_1371_journal_pone_0081200 crossref_primary_10_1016_j_ajog_2012_06_068 crossref_primary_10_1016_j_amepre_2012_04_003 crossref_primary_10_3389_fimmu_2022_1005344 crossref_primary_10_1016_j_vaccine_2016_05_032 crossref_primary_10_1371_journal_pone_0047448 crossref_primary_10_1080_21645515_2015_1127485 crossref_primary_10_2139_ssrn_3381953 crossref_primary_10_4069_kjwhn_2011_17_3_205 crossref_primary_10_1016_j_amepre_2019_05_018 crossref_primary_10_1016_j_antinf_2015_08_001 crossref_primary_10_1016_j_vaccine_2014_04_063 crossref_primary_10_1080_08964289_2021_1987853 crossref_primary_10_1016_j_vaccine_2013_08_081 crossref_primary_10_1542_peds_2022_059922 crossref_primary_10_1038_s41598_018_32193_9 crossref_primary_10_1093_infdis_jiab345 crossref_primary_10_1016_j_jpp_2020_12_007 crossref_primary_10_1016_j_vaccine_2022_03_042 crossref_primary_10_1111_jpc_15857 crossref_primary_10_2217_fmb_2017_0096 crossref_primary_10_3390_vaccines10071083 crossref_primary_10_1016_j_jvacx_2023_100387 crossref_primary_10_1016_j_vaccine_2013_02_053 crossref_primary_10_1016_j_vaccine_2022_04_087 crossref_primary_10_1016_j_clinthera_2016_08_005 crossref_primary_10_1089_jwh_2011_2794 crossref_primary_10_1111_irv_12180 crossref_primary_10_1097_AOG_0000000000005479 crossref_primary_10_1016_j_vaccine_2012_06_082 crossref_primary_10_1016_j_vaccine_2012_09_034 crossref_primary_10_1093_infdis_jiad539 crossref_primary_10_1186_s12884_018_2051_3 crossref_primary_10_1371_journal_pone_0157041 crossref_primary_10_1016_j_jiac_2015_01_015 crossref_primary_10_1093_infdis_jir440 crossref_primary_10_3389_fped_2021_638871 crossref_primary_10_1097_AOG_0000000000000581 crossref_primary_10_1136_bmjopen_2020_040226 crossref_primary_10_1371_journal_pntd_0007648 crossref_primary_10_1016_j_vaccine_2017_08_017 crossref_primary_10_1186_s12884_017_1275_y crossref_primary_10_1097_EDE_0000000000001116 crossref_primary_10_1177_2515135519826481 crossref_primary_10_1016_S0001_4079_19_31793_5 crossref_primary_10_1016_j_vaccine_2021_11_011 crossref_primary_10_3109_14767058_2012_663835 crossref_primary_10_1016_j_vaccine_2014_08_061 crossref_primary_10_1542_peds_2020_0375 crossref_primary_10_1080_21645515_2017_1279772 crossref_primary_10_1371_journal_pone_0148421 crossref_primary_10_1097_AOG_0000000000003161 crossref_primary_10_3390_biom13020202 crossref_primary_10_1080_07853890_2017_1421320 crossref_primary_10_1093_infdis_jiv138 crossref_primary_10_1016_S1701_2163_16_35336_1 crossref_primary_10_15585_mmwr_rr6505a1 crossref_primary_10_1016_j_vaccine_2017_04_045 crossref_primary_10_1016_S0929_693X_11_71020_X crossref_primary_10_1080_07399332_2014_942903 crossref_primary_10_1097_INF_0000000000000321 crossref_primary_10_1016_j_vaccine_2012_10_027 crossref_primary_10_7759_cureus_30666 crossref_primary_10_1007_s40272_017_0231_7 crossref_primary_10_1002_14651858_CD001269_pub5 crossref_primary_10_1002_14651858_CD001269_pub6 crossref_primary_10_1080_21645515_2019_1667202 crossref_primary_10_1177_1753495X15604099 crossref_primary_10_1136_bmjopen_2019_030277 crossref_primary_10_1371_journal_pone_0189623 crossref_primary_10_1136_bmjopen_2011_000851 crossref_primary_10_1016_j_vaccine_2020_07_014 crossref_primary_10_1016_j_vaccine_2013_01_058 crossref_primary_10_1111_irv_12674 crossref_primary_10_1177_003335491312800103 crossref_primary_10_5402_2013_879493 crossref_primary_10_1016_j_vaccine_2015_07_109 crossref_primary_10_1016_j_lpm_2013_01_064 crossref_primary_10_1038_s41598_017_05940_7 crossref_primary_10_3389_fimmu_2014_00446 crossref_primary_10_1002_cncr_30467 crossref_primary_10_1111_phn_12099 crossref_primary_10_1016_j_ijid_2019_12_019 crossref_primary_10_1080_14760584_2016_1175304 crossref_primary_10_1093_cid_ciz1058 crossref_primary_10_1080_14767058_2019_1680633 crossref_primary_10_1097_AOG_0b013e318263a278 crossref_primary_10_1097_INF_0000000000000873 crossref_primary_10_7326_M21_3668 crossref_primary_10_1080_14760584_2018_1471988 crossref_primary_10_1111_irv_12649 crossref_primary_10_1016_j_jtauto_2021_100122 crossref_primary_10_1093_cid_cit750 crossref_primary_10_1007_s10096_011_1297_8 crossref_primary_10_1093_infdis_jiw033 crossref_primary_10_1016_j_vaccine_2017_05_045 crossref_primary_10_1038_s41372_020_0668_3 crossref_primary_10_1016_j_vaccine_2014_03_075 crossref_primary_10_5694_mja2_51989 crossref_primary_10_1186_s12985_017_0787_4 crossref_primary_10_1016_j_ijid_2020_01_033 crossref_primary_10_1016_j_vaccine_2011_04_048 crossref_primary_10_1080_21645515_2024_2350090 crossref_primary_10_3390_pathogens8040265 crossref_primary_10_1093_infdis_jiz670 crossref_primary_10_1080_21645515_2024_2394255 crossref_primary_10_1080_21645515_2024_2403831 crossref_primary_10_1097_01_AOG_0000428788_74725_90 crossref_primary_10_1128_mBio_00176_20 crossref_primary_10_1016_j_vaccine_2016_03_034 crossref_primary_10_1093_infdis_jiz310 crossref_primary_10_4049_immunohorizons_1700057 crossref_primary_10_1007_s40259_023_00596_4 crossref_primary_10_1590_S1679_45082013000100010 crossref_primary_10_1016_j_vaccine_2017_05_050 crossref_primary_10_1136_bmj_l4151 crossref_primary_10_1111_ijcp_13361 crossref_primary_10_1097_INF_0000000000000529 crossref_primary_10_1007_s40272_023_00606_6 crossref_primary_10_1111_tmi_13515 crossref_primary_10_2217_fmb_11_15 crossref_primary_10_1016_j_vaccine_2020_11_032 crossref_primary_10_3390_vaccines12111251 crossref_primary_10_3390_vaccines11111712 crossref_primary_10_1016_j_bjid_2024_104465 crossref_primary_10_1007_s10995_013_1352_4 crossref_primary_10_1016_j_vaccine_2019_05_034 crossref_primary_10_1080_21645515_2016_1215392 crossref_primary_10_1111_j_1469_0691_2012_03942_x crossref_primary_10_1016_j_cell_2021_02_031 crossref_primary_10_1128_CVI_00136_17 crossref_primary_10_1056_NEJMoa1401480 crossref_primary_10_1097_MOP_0b013e32834e8fe9 crossref_primary_10_1111_ped_12888 crossref_primary_10_1097_AOG_0b013e318242af27 crossref_primary_10_1016_j_vaccine_2023_02_074 crossref_primary_10_1007_s00103_016_2467_8 crossref_primary_10_3389_fimmu_2023_1146082 crossref_primary_10_1016_j_ajog_2011_02_042 crossref_primary_10_1016_j_vaccine_2019_12_056 crossref_primary_10_1016_j_vaccine_2020_05_036 crossref_primary_10_11124_jbisrir_2014_1269 crossref_primary_10_1007_s00431_017_3001_1 crossref_primary_10_2217_fmb_11_106 crossref_primary_10_1080_21645515_2017_1345385 crossref_primary_10_1016_j_ajog_2012_07_009 crossref_primary_10_1155_2012_538701 crossref_primary_10_1007_s13312_024_3151_y crossref_primary_10_1007_BF03404197 crossref_primary_10_2105_AJPH_2017_303887 crossref_primary_10_1093_infdis_jis377 crossref_primary_10_1016_j_lpm_2015_04_012 crossref_primary_10_1136_bmjopen_2014_005676 crossref_primary_10_1111_irv_12465 crossref_primary_10_1080_21645515_2018_1507585 crossref_primary_10_1007_s10995_012_1104_x crossref_primary_10_1056_NEJMoa2106062 crossref_primary_10_12688_f1000research_12473_1 crossref_primary_10_1371_journal_pone_0070867 crossref_primary_10_1177_003335491513000104 crossref_primary_10_1016_j_vaccine_2011_08_013 crossref_primary_10_12688_f1000research_148519_1 crossref_primary_10_1016_j_vaccine_2016_04_057 crossref_primary_10_12688_f1000research_148519_2 crossref_primary_10_1016_j_vaccine_2023_12_020 crossref_primary_10_1101_cshperspect_a038430 crossref_primary_10_1111_jmwh_12621 crossref_primary_10_3390_v13071392 crossref_primary_10_4103_jfmpc_jfmpc_229_23 crossref_primary_10_3389_fimmu_2022_1031924 crossref_primary_10_1371_journal_pone_0197867 crossref_primary_10_1186_1471_2296_15_102 crossref_primary_10_1016_j_vaccine_2015_12_004 crossref_primary_10_1155_2014_950316 crossref_primary_10_1016_j_ogc_2014_08_002 crossref_primary_10_1016_j_ogc_2014_08_001 crossref_primary_10_1128_JVI_02422_16 crossref_primary_10_3389_fimmu_2020_00810 crossref_primary_10_1097_INF_0000000000001258 crossref_primary_10_4161_hv_8_1_18601 crossref_primary_10_1542_peds_2012_1255 crossref_primary_10_1097_AOG_0000000000002588 crossref_primary_10_1111_pai_12549 crossref_primary_10_1016_j_crmicr_2023_100202 crossref_primary_10_1016_j_ogc_2018_01_006 crossref_primary_10_5124_jkma_2016_59_7_523 crossref_primary_10_1128_CVI_00565_15 crossref_primary_10_1542_peds_2010_2041 crossref_primary_10_1080_14760584_2021_1915138 crossref_primary_10_1093_cid_cix241 crossref_primary_10_3389_fviro_2022_849995 crossref_primary_10_1016_j_whi_2019_04_017 crossref_primary_10_1089_jwh_2022_0030 crossref_primary_10_3389_fimmu_2022_910383 crossref_primary_10_1186_s12884_020_03243_w crossref_primary_10_1080_08989621_2012_678686 crossref_primary_10_1111_irv_12320 |
| ContentType | Journal Article |
| Copyright | 2010 The Infectious Diseases Society of America 2010 by the Infectious Diseases Society of America 2010 2015 INIST-CNRS Copyright University of Chicago, acting through its Press Dec 15, 2010 |
| Copyright_xml | – notice: 2010 The Infectious Diseases Society of America – notice: 2010 by the Infectious Diseases Society of America 2010 – notice: 2015 INIST-CNRS – notice: Copyright University of Chicago, acting through its Press Dec 15, 2010 |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 5PM |
| DOI | 10.1086/657309 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Virology and AIDS Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| EndPage | 1361 |
| ExternalDocumentID | PMC3106242 2208957581 21058908 23508293 10_1086_657309 10.1086/657309 29764739 ark_67375_HXZ_RVW5M4ML_N |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural Feature |
| GeographicLocations | New England Northeastern states |
| GeographicLocations_xml | – name: New England – name: Northeastern states |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR000142 – fundername: NCRR NIH HHS grantid: UL1 RR024139 – fundername: NIAID NIH HHS grantid: K23 AI68280 – fundername: NIAID NIH HHS grantid: K23 AI068280 – fundername: NCRR NIH HHS grantid: KL2 RR024138 – fundername: NCRR NIH HHS grantid: K24 RR022477 – fundername: NCRR NIH HHS grantid: KL2RR024138 |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HVGLF HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION .GJ 1KJ 3O- 70D AAPGJ AAPNW AAWDT ABKDP ABNKS ABSMQ ABZBJ ACFRR ACPQN ACVCV ACZBC ADEYI ADMTO ADOCK AEKPW AFFQV AFSHK AFYAG AGKEF AGKRT AGMDO AHGBF AI. AIJHB AJDVS APJGH AQDSO AVNTJ BZKNY EIHJH HQ3 HTVGU IQODW J5H MBLQV OBFPC O~Y VH1 Y6R ZGI CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 5PM |
| ID | FETCH-LOGICAL-c508t-1df48201197ffb83a8f5c9bd49068d4144d1aa682f4dd94ccf71d4d95843263f3 |
| ISSN | 1058-4838 1537-6591 |
| IngestDate | Thu Aug 21 13:33:15 EDT 2025 Fri Jul 11 10:26:50 EDT 2025 Fri Jul 25 05:22:02 EDT 2025 Tue Aug 05 11:44:24 EDT 2025 Mon Jul 21 09:16:23 EDT 2025 Tue Jul 01 01:25:49 EDT 2025 Thu Apr 24 22:55:43 EDT 2025 Wed Sep 11 04:50:50 EDT 2024 Thu Jun 19 15:34:21 EDT 2025 Tue Aug 05 16:49:44 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Human Infection Pregnancy Prevention Immunoprophylaxis Viral disease Influenza Female Infant Hospitalization Vaccine Woman |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c508t-1df48201197ffb83a8f5c9bd49068d4144d1aa682f4dd94ccf71d4d95843263f3 |
| Notes | istex:8ED1D03EAD64CDD02D9D49807997F6E3C653FFC6 ark:/67375/HXZ-RVW5M4ML-N SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/cid/article-pdf/51/12/1355/899307/51-12-1355.pdf |
| PMID | 21058908 |
| PQID | 816815842 |
| PQPubID | 48300 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3106242 proquest_miscellaneous_808464661 proquest_journals_816815842 pubmed_primary_21058908 pascalfrancis_primary_23508293 crossref_primary_10_1086_657309 crossref_citationtrail_10_1086_657309 oup_primary_10_1086_657309 jstor_primary_29764739 istex_primary_ark_67375_HXZ_RVW5M4ML_N |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-12-15 |
| PublicationDateYYYYMMDD | 2010-12-15 |
| PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAbbrev | Clin Infect Dis |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2010 |
| Publisher | The University of Chicago Press University of Chicago Press Oxford University Press |
| Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press – name: Oxford University Press |
| References | 17146026 - Arch Pediatr Adolesc Med. 2006 Dec;160(12):1277-83 15367555 - JAMA. 2004 Sep 15;292(11):1333-40 479636 - J Infect Dis. 1979 Aug;140(2):141-6 16237376 - MMWR Morb Mortal Wkly Rep. 2005 Oct 21;54(41):1050-2 14561957 - MMWR Morb Mortal Wkly Rep. 2003 Oct 17;52(41):987-92 17938054 - J Clin Epidemiol. 2007 Nov;60(11):1127-31 16731574 - Epidemiol Rev. 2006;28:47-53 10761514 - Pediatr Clin North Am. 2000 Apr;47(2):449-63 8354906 - J Infect Dis. 1993 Sep;168(3):647-56 15311370 - Am J Perinatol. 2004 Aug;21(6):333-9 9302748 - Vaccine. 1997 Aug-Sep;15(12-13):1379-84 18799552 - N Engl J Med. 2008 Oct 9;359(15):1555-64 11301819 - Infect Dis Clin North Am. 2001 Mar;15(1):253-71 3668509 - J Gen Virol. 1987 Oct;68 ( Pt 10):2681-6 10648763 - N Engl J Med. 2000 Jan 27;342(4):225-31 3588113 - Pediatr Infect Dis J. 1987 Apr;6(4):398-403 19644442 - MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52 2304146 - J Virol. 1990 Mar;64(3):1370-4 16738159 - Obstet Gynecol. 2006 Jun;107(6):1323-9 4164125 - Lancet. 1967 Apr 8;1(7493):757-9 11991880 - Am J Respir Crit Care Med. 2002 May 1;165(9):1285-9 18639488 - J Clin Virol. 2008 Oct;43(2):148-51 5950290 - Nature. 1966 Jun 4;210(5040):1070-1 6848601 - J Immunol. 1983 Feb;130(2):932-6 7462695 - J Infect Dis. 1980 Dec;142(6):844-9 |
| References_xml | – reference: 16738159 - Obstet Gynecol. 2006 Jun;107(6):1323-9 – reference: 17938054 - J Clin Epidemiol. 2007 Nov;60(11):1127-31 – reference: 17146026 - Arch Pediatr Adolesc Med. 2006 Dec;160(12):1277-83 – reference: 11991880 - Am J Respir Crit Care Med. 2002 May 1;165(9):1285-9 – reference: 19644442 - MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52 – reference: 7462695 - J Infect Dis. 1980 Dec;142(6):844-9 – reference: 10648763 - N Engl J Med. 2000 Jan 27;342(4):225-31 – reference: 18639488 - J Clin Virol. 2008 Oct;43(2):148-51 – reference: 16731574 - Epidemiol Rev. 2006;28:47-53 – reference: 18799552 - N Engl J Med. 2008 Oct 9;359(15):1555-64 – reference: 3668509 - J Gen Virol. 1987 Oct;68 ( Pt 10):2681-6 – reference: 2304146 - J Virol. 1990 Mar;64(3):1370-4 – reference: 16237376 - MMWR Morb Mortal Wkly Rep. 2005 Oct 21;54(41):1050-2 – reference: 3588113 - Pediatr Infect Dis J. 1987 Apr;6(4):398-403 – reference: 5950290 - Nature. 1966 Jun 4;210(5040):1070-1 – reference: 8354906 - J Infect Dis. 1993 Sep;168(3):647-56 – reference: 479636 - J Infect Dis. 1979 Aug;140(2):141-6 – reference: 9302748 - Vaccine. 1997 Aug-Sep;15(12-13):1379-84 – reference: 15311370 - Am J Perinatol. 2004 Aug;21(6):333-9 – reference: 14561957 - MMWR Morb Mortal Wkly Rep. 2003 Oct 17;52(41):987-92 – reference: 10761514 - Pediatr Clin North Am. 2000 Apr;47(2):449-63 – reference: 15367555 - JAMA. 2004 Sep 15;292(11):1333-40 – reference: 4164125 - Lancet. 1967 Apr 8;1(7493):757-9 – reference: 6848601 - J Immunol. 1983 Feb;130(2):932-6 – reference: 11301819 - Infect Dis Clin North Am. 2001 Mar;15(1):253-71 |
| SSID | ssj0011805 |
| Score | 2.4932775 |
| Snippet | Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most... Background. Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most... Infants aged <12 months are at high risk of hospitalization for influenza. Influenza vaccine is recommended for pregnant women and for most children; however,... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref oup jstor istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1355 |
| SubjectTerms | and Commentaries Antibodies ARTICLES AND COMMENTARIES Babies Biological and medical sciences Case-Control Studies Chronic diseases Female Hospital admissions Hospitalization Hospitalization - statistics & numerical data Human viral diseases Humans Immunity, Maternally-Acquired Infant Infant, Newborn Infants Infections Infectious diseases Influenza Influenza vaccines Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Influenza, Human - epidemiology Influenza, Human - prevention & control Male Medical sciences Mothers New England Pregnancy Treatment Outcome Vaccination Vaccines Viral diseases Viral diseases of the respiratory system and ent viral diseases Womens health |
| Title | Influenza Vaccine Given to Pregnant Women Reduces Hospitalization Due to Influenza in Their Infants |
| URI | https://api.istex.fr/ark:/67375/HXZ-RVW5M4ML-N/fulltext.pdf https://www.jstor.org/stable/29764739 https://www.ncbi.nlm.nih.gov/pubmed/21058908 https://www.proquest.com/docview/816815842 https://www.proquest.com/docview/808464661 https://pubmed.ncbi.nlm.nih.gov/PMC3106242 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZbxMxELaiVkJICHEVtoXiB-AlWrSHvccjomkTaAJCSYl4WXntXboCbaIcAvUH8TsZX7tJWyrgJYrWjpN4Po9n7G9mEHpBScxyXwSuICxySS5JACQOXc6p4CItYX3JAOfhKOpPyLspnXY6vzZYS-tV_ppfXBtX8j9ShWcgVxkl-w-SbQaFB_Ae5AuvIGF4_SsZD3SFkQvWPWNc3pB3T6Tykvbkx0XxVXJcuqpEJcyiWEvulS0TYqIvu0drVTqjHaiqJQmjWshHzKR5ajIZ2ChKy-BaL-0FT3vYXtSzH5UqEtsdLBnjjcmu-WEzTaSvatbWez5ZMK5PzrXKgbaWh3zO5pWOxemtYSIK02QOKjTpQ4dq3hQAuaF7ParONrU6Lqw-jt2I6oJeVmGbDLUGmMGG-vVDnfP3yr7gqWuqiII-S9udz972jz5kx5PT02zcm463W9VGHwRekoJZKyP8dwNwR2SljKPB--a2yk8UVbb5Axs1rPRXbhk9u3L9_rT8VxtYeWfOliDBUpdTuc7fuUzb3bCDxvfQXePA4DcajfdRp6gfoFtDQ9F4iHiDJWxAiRUo8WqGLSixAiU2oMSXQIkBlLJ3O1BVYwVKbED5CE2Oe-O3fddU8nA5OAAr1xclUaZmGpdlnoQsKSlPc0FSL0oEAade-IxFSVASIVLCeRn7gogUrGNwL8Iy3EM79awuniAcSvuKRRHsjhFhXph7EQuoIB6juZfEzEEv7VRn3KS5l9VWvmeKbpFEmRaJg543_eY6scuVHq-UpJpmtvgmaZAxzfrTL9mns890SIan2chBe0qUTccAbHxQeDDCPsj2j8Mfbom8_XRIZcB76KADi4HMKJ1lJsvk-DAtgYNw0wo7grzmY3UBCz9LPPApCNjdDnqsAdMOLSGaeomD4i0oNR1ksvntlro6V0nnwQ2UoWT7N_6oA3S7XflP0c5qsS6egdG-yg_VivkNMpnulg |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influenza+Vaccine+Given+to+Pregnant+Women+Reduces+Hospitalization+Due+to+Influenza+in+Their+Infants&rft.jtitle=Clinical+infectious+diseases&rft.au=Benowitz%2C+Isaac&rft.au=Esposito%2C+Daina+B&rft.au=Gracey%2C+Kristina+D&rft.au=Shapiro%2C+Eugene+D&rft.date=2010-12-15&rft.pub=Oxford+University+Press&rft.issn=1058-4838&rft.eissn=1537-6591&rft.volume=51&rft.issue=12&rft.spage=1355&rft_id=info:doi/10.1086%2F657309&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=2208957581 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |